Bortezomib‐based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data

Autor:	Michal Sýkora, Lukas Stejskal, Alexandra Jungova, Vladimir Maisnar, Petr Kessler, Viera Sandecká, Jana Ullrychova, Adriana Heindorfer, Luděk Pour, Tomas Pika, Jan Straub, Martin Stork, Jiří Minařík, Lucie Brožová, Roman Hájek, Ivan Spicka, Tomas Jelinek, Petr Pavlicek, David Starostka, Sabina Ševčíková, Jakub Radocha, Marek Wrobel
Rok vydání:	2021
Předmět:	Male Oncology medicine.medical_specialty Anemia Newly diagnosed Dexamethasone Disease-Free Survival Bortezomib 03 medical and health sciences 0302 clinical medicine Autologous stem-cell transplantation hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Registries Cyclophosphamide Melphalan Multiple myeloma Aged Czech Republic 030304 developmental biology Aged 80 and over 0303 health sciences business.industry Hematology General Medicine Middle Aged medicine.disease Thalidomide 3. Good health Clinical trial Regimen Treatment Outcome Doxorubicin 030220 oncology & carcinogenesis Monoclonal Prednisone Female Multiple Myeloma business medicine.drug
Zdroj:	European Journal of Haematology. 107:466-474
ISSN:	1600-0609 0902-4441
DOI:	10.1111/ejh.13683
Popis:	Objectives This study compared the use of bortezomib in different combination regimens in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible. Patients and methods We analyzed data from the Registry of Monoclonal Gammopathies (RMG) of the Czech Myeloma Group (CMG) to provide real-world evidence of outcome for 794 newly diagnosed MM transplant ineligible patients. The most frequently used regimen was VCd (bortezomib-cyclophosphamide-dexamethasone) (47.5%) over VMP (bortezomib-melphalan-prednisone) (21.7%), BDd (bortezomib-doxorubicin-dexamethasone) (9.8%) and VTd (bortezomib-thalidomide-dexamethasone) (2.9%). Results The overall response rate (ORR) was 69.2% (478/691), including 12.6% (≥ CR); 34.7% very good partial responses (VGPR); 21.9% partial responses (PR). Among triplet regimens, VMP was the most effective regimen compared to VCd, BDd and VTd. Median PFS was 22.3 vs. 18.5 vs. 13.7 vs. 13.8 months, (p=0.275), respectively and median OS was 49 vs. 41.7 vs. 37.9 vs. 32.2 months (p=0.004), respectively. The most common grade 3-4 toxicities were anemia in 17.4% and infections in 18% of patients. Conclusion Our study confirmed that bortezomib-based treatment is effective and safe in NDMM transplant ineligible patients; especially VMP, which was identified as superior between bortezomib-based induction regimens not only in clinical trials, but also in real clinical practice.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e1c1a0103ebd62cfdd0ad071e031465 https://doi.org/10.1111/ejh.13683 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.